Histological and molecular responses to pemafibrate in MASLD with hypertriglyceridemia: the CLARITY study

Background & Aims: The histological effects and underlying molecular responses to pemafibrate in MASLD remain poorly defined. We investigated longitudinal histological changes and cell-type-specific molecular responses in patients with MASLD and hypertriglyceridemia. Methods: In the prospective, single-arm CLARITY study, 33 patients with MASLD and hypertriglyceridemia received pemafibrate (0.2 mg/day) and underwent paired liver biopsies at baseline and 52 weeks. Primary outcomes were changes in fibrosis stage and NAFLD activity score (NAS). Complementary analyses included dual-energy X-ray abs

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.